 AtriCure, Inc. Nasdaq: ATRC, a leading innovator in treatments for atrial fibrillation Afib and left atrial appendage LAA management, today announced the pricing of its underwritten offering of 3,977,273 shares of its common stock at a price to the public of 44.00 per share pursuant to its existing automatic shelf registration statement. Gross proceeds to AtriCure from the offering are expected to be approximately 175 million, before deducting underwriting discounts and commissions and estimated offering expenses. AtriCure has granted to the underwriters of the offering a 30-day option to purchase up to an additional 596,590 shares of common stock on the same terms and conditions. The offering is expected to close on May 14, 2020, subject to customary closing conditions. AtriCure intends to use the net proceeds from the offering for working capital and other general corporate purposes, which may include repayment of debt or long-term liabilities, and other potential corporate or market development activities. 